Ir para o conteúdo principal

Phio Pharmaceuticals (NASDAQ: PHIO) — Perfil da empresa, notícias e dados financeiros

Logo de Phio Pharmaceuticals
PHIO Phio Pharmaceuticals
Phio Pharmaceuticals  primary media
Perfil da empresa

Phio Pharmaceuticals

Phio Pharmaceuticals (NASDAQ:PHIO) is a biotechnology firm focused on developing innovative cancer treatments. Its operations revolve around pioneering a new class of therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) technology, aimed at empowering the immune system to fight tumors more effectively. The company's projects primarily involve preclinical and clinical research to design therapies that silence tumor-induced suppression of the immune system, thus enhancing the effectiveness of cancer treatments. Phio Pharmaceuticals strives to break new ground in cancer therapy, with the objective of bringing novel, more effective treatments to patients in need, demonstrating its commitment to advancing the fight against cancer through cutting-edge research and development.

Resumo

Public USParticipação acionária
2011Ano de fundação
10Funcionários
Marlborough, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Phio Pharmaceuticals

  • INTASYL platform, an RNAi technology addressing immune-oncology targets.
  • PH-762 aimed at enhancing T-cell function against cancer cells.
  • PH-894 for the deployment in solid tumors treatment.
  • PH-804 as an immunotherapy for T-cell activation in cancer.
  • Collaboration with Medigene AG for TCR-T cell therapy enhancers.
  • Research partnership for developing INTASYL applications in various therapeutic areas.

equipe executiva do Phio Pharmaceuticals

  • Robert J. BittermanPresident, CEO & Chairman
  • Lisa C. CarsonCFO, Principal Accounting Officer and VP of Finance & Administration
  • Linda M. MahoneySenior Vice President of Development
  • Jennifer PhillipsSenior Vice President of Regulatory & Corporate Affairs

Principais indicadores financeiros

Resultados divulgados pela Phio Pharmaceuticals , em USD.

Cap. de mercado
10,7 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.3
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Phio Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-9,2 mi-8,7 mi
0-7,4 mi-7,2 mi
0-10,8 mi-10,8 mi
0-11,5 mi-11,3 mi